Back

dr. N. (Neeltje) Steeghs

dr. N. (Neeltje) Steeghs

Assistant Professor - medical
dr. N. (Neeltje) Steeghs
  • Dept of Medical Oncology

Biography

Biography

Neeltje Steeghs, M.D., Ph.D. is a licensed Medical Oncologist and Clinical Pharmacologist.  She served as chair of the Dutch Pharmacology Oncology Group and chair of the Dutch GIST consortium. Her main scientific interests are new drug development, including the  performance of clinical phase I and early phase II trials, and the inclusion of pharmacokinetics and pharmacodynamics in these studies. She also has a major interest in the design aspects of early clinical studies.
Besides her clinical activities, she has been Clinical Assessor for the Medicines Evaluation Board of the European Medicines Agency (2009-2011), chair of the Dutch Sarcoma Study Group, board member for the Paediatric Oncology Research Foundation (2010-2013), Young investigator for the EORTC Soft Tissue and Bone Sarcoma Group (2013-2016), chair of the multidisciplinary expert board for the Center for Personalized Cancer Treatment (2012-2015) and Vice-Chair of the Medical Ethical Committee of the Netherlands Cancer Institute. She has also been board member for the Dutch Oncological Medicine Evaluation Board, the National Working Party for Cancer Drugs Interactions and the Translational Research Board of the Netherlands Cancer Institute. She has a.o. been editor of Gastrointestinal Stromal Tumor (GIST), and Pharmacology of Anti-Cancer Drugs.
She currently serves as Director for the National Platform of Early Phase Clinical Trials at Oncode Accelerator/University Medical Center Utrecht, as Director of the Early Drug Development Center and Clinical Research at the Netherlands Cancer Institute, in Amsterdam, the Netherlands and as advisor for several pharmaceutical companies.
Neeltje Steeghs has been principle investigator for many investigator initiated and industry sponsored clinical trials. She is regarded as a leading authority on mechanisms for safe and effective dosing of anticancer agents. She has authored or co-authored over 200 scientific papers, and has given numerous lectures on a variety of topics at international meetings.
Neeltje Steeghs was invited to join the ESMO 2024 Scientific Committee as member of the Developmental therapeutics track.

Research Output (75)

Sunitinib for the treatment of metastatic gastrointestinal stromal tumors:the effect of TDM-guided dose optimization on clinical outcomes

Giraud E. L., Westerdijk K., van der Kleij M. B.A., Guchelaar N. A.D., Meertens M., Bleckman R. F., Rieborn A., Mohammadi M., Roets E., Mathijssen R. H.J., Huitema A. D.R., Koolen S. L.W., Gelderblom H., Moes D. J.A.R., Reyners A. K.L., Touw D. J., Keizer-Heldens P., Oosten A. W., van der Graaf W. T.A., Steeghs N., van Erp N. P., Desar I. M.E., Jun 2024, In: ESMO open. 9

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Lin Lishi, Barkman Hannerieke J., Smit Egbert F., De Langen Adrianus J., Steeghs Neeltje, Beijnen Jos H., Huitema Alwin D.R. 1 Feb 2024, In: Therapeutic drug monitoring. 46 , p. 73-79 7 p.

The use of microtracers in food-effect trials:An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

van der Heijden L. T., Steeghs N., Beijnen J. H., Huitema A. D.R., Dorlo T. P.C. Dec 2023, In: Clinical and Translational Science. 16 , p. 2557-2564 8 p.

Are novel oral oncolytics underdosed in obese patients?

Lin Lishi, van der Meer Ellen K O, Steeghs Neeltje, Beijnen Jos H, Huitema Alwin D R 31 Oct 2023, In: Cancer Chemotherapy and Pharmacology. 93 , p. 129-136 8 p.

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

van der Kleij Maud B A, Guchelaar Niels A D, Mathijssen Ron H J, Versluis Jurjen, Huitema Alwin D R, Koolen Stijn L W, Steeghs Neeltje Oct 2023, In: Clinical Pharmacokinetics. 62 , p. 1333-1364 32 p.

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling

Angus Lindsay, Smid Marcel, Wilting Saskia M, Bos Manouk K, Steeghs Neeltje, Konings Inge R H M, Tjan-Heijnen Vivianne C G, van Riel Johanna M G H, van de Wouw Agnes J, Cpct Consortium , Cuppen Edwin, Lolkema Martijn P, Jager Agnes, Sleijfer Stefan, Martens John W M 4 Sep 2023, In: Cancers. 15 14 p.

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

van Eerden Ruben A G, IJzerman Nikki S, van Meekeren Milan, Oomen-de Hoop Esther, Guchelaar Niels A D, Visser Andrea M W, Matic Maja, van Schaik Ron H N, de Bruijn Peter, Moes Dirk-Jan A R, Jobse Pieter A, Gelderblom Hans, Huitema Alwin D R, Steeghs Neeltje, Mathijssen Ron H J, Koolen Stijn L W, Aug 2023, In: Clinical Pharmacokinetics. 62 , p. 1129-1139 11 p.

Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients

Lanser Daan A C, Van der Kleij Maud B A, Veerman G D Marijn, Steeghs Neeltje, Huitema Alwin D R, Mathijssen Ron H J, Oomen-de Hoop Esther Jul 2023, In: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 163 6 p.

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Groenland Stefanie L, Janssen J M, Nijenhuis C M, de Vries N, Rosing H, Wilgenhof S, van Thienen J V, Haanen J B A G, Blank C U, Beijnen J H, Huitema A D R, Steeghs N Jun 2023, In: Cancer Chemotherapy and Pharmacology. 91 , p. 447-456 10 p.

Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer

Mohmaed Ali Ma Ida, Bruin Maaike A C, Dezentjé Vincent O, Beijnen Jos H, Steeghs Neeltje, Huitema Alwin D R May 2023, In: Pharmaceutical Research. 40 , p. 1239-1247 9 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Contact

Afspraken

Praktisch

hetwkz.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not